-
I-Mab CEO Outlines Streamlined US Entity’s Focus and Potential for In-Licensing
•
I-Mab (NASDAQ: IMAB), a biopharmaceutical company that recently restructured into separate US and Chinese entities, has detailed its current strategic direction and streamlined operations. US CEO Raj Kannan discussed the company’s new focus at an investor conference, as reported by Endpoints News with a transcript from AlphaSense. This marks Kannan’s…
-
Hainan Medical Zone Launches ‘Lecheng Global Special Medical Insurance’ for Wider Drug Access
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has launched the “Lecheng Global Special Medical Insurance,” a new initiative that allows immediate patient enrollment. In conjunction with this launch, the Hainan Boao Lecheng Medical and Commercial Integration Research and Development Center, H2 Global Assistance Sdn Bhd, and Yuan Xin…
-
Hengrui Medicine Gets NMPA Approval for Clinical Study of CDK 4/6 Inhibitor Combo in Breast Cancer
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for the combination of dalpiciclib (SHR6390) and HRS8807 in the treatment of breast cancer. Dalpiciclib, the first domestically-developed…
-
Blue Shield Pharma Faces Bankruptcy Proceedings After Missing Debt Payments
•
The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield Pharma, a China-based pharmaceutical company specializing in tumor drug development. The move comes after Blue Shield Pharma failed to meet its debt obligations. As of April 9, 2024, the company’s total employee debt stood at…
-
Roche and Eli Lilly’s Elecsys pTau217 Blood Test Earns FDA Breakthrough Designation for Alzheimer’s Detection
•
The U.S. Food and Drug Administration (FDA) has granted a breakthrough device designation for Elecsys pTau217, a blood test co-developed by Roche (SWX: ROG) and Eli Lilly (NYSE: LLY), aimed at detecting amyloid pathology, a hallmark of Alzheimer’s disease. This designation is significant in the context of the growing global…
-
3SBio Secures NMPA Approval for Pediatric Thrombopoietin Treatment of ITP
•
3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its thrombopoietin product, used in the treatment of persistent or chronic primary immune thrombocytopenia (ITP) in children or adolescents. This marks a significant…
-
Bayer Partners with Hologic to Develop Contrast-Enhanced Mammography Solution for Breast Cancer Diagnosis
•
Bayer (ETR: BAYN), a multinational pharmaceutical and life sciences company headquartered in Germany, has announced a strategic partnership with Hologic (NASDAQ: HOLX), a leading women’s health specialist. The collaboration aims to develop a contrast-enhanced mammography (CEM) solution that serves as a cost-effective adjunct to traditional mammography for breast cancer diagnosis.…
-
AbbVie’s Aquipta/Qulipta Shows Promise in Migraine Prevention Trial
•
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, last week released interim results from a Phase III open-label trial of its CGRP receptor antagonist, Aquipta/Qulipta (atogepant), for the prevention of migraines in patients with chronic or episodic migraine. The data, collected between weeks 13 to 16, indicated that the average…
